1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

BMS option pact injects new life into Biocon's oral insulin

 
• By Anju Ghangurde

Biocon has entered into an agreement with Bristol-Myers Squibb, under which the US multinational holds an exclusive option to further develop and commercialize the Indian firm's prandial oral insulin candidate, IN-105, pending the outcome of certain clinical trials.

Biocon has entered into an agreement with Bristol-Myers Squibb, under which the US multinational holds an exclusive option to further develop and commercialize the Indian firm's prandial oral insulin candidate, IN-105, pending the outcome of certain clinical trials.

The pact infuses a fresh lease of life into IN-105, which had earlier failed to meet its primary endpoint of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.

Metabolic Disease-Focused Poxel Teeters On The Edge

 
• By Andrew McConaghie

The Lyon, France-based company has filed for insolvency and is running out of time to find new funding for its metabolic disease pipeline.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

More from Therapeutic Category

Sumitomo Parkinson’s Filing A Pivotal Moment For Japan’s iPSC Ambitions

 
• By Lisa Takagi

Sumitomo Pharma's iPSC therapy for Parkinson's has been filed for approval in Japan after showing safety and efficacy in a Phase I/II trial and may become one of the first such therapies to reach the market in the country, which has invested heavily in the modality.

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

 
• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.

Direct-To-Consumer And Lower Prices Key To Novo Nordisk’s Wegovy Fightback

 
• By Andrew McConaghie

The company’s incoming CEO Mike Doustdar has promised greater agility, competitiveness and execution, but investors are yet to be convinced.